Advanced searches left 3/3

Metastatic Pancreatic Neuroendocrine - Europe PMC

Summarized by Plex Scholar
Last Updated: 08 February 2022

* If you want to update the article please login/register

Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.

Pancreatic neuroendocrine tumors are rare disorders that account for 1% to 3% of all malignant pancreatic neoplasms. Patients with metastatic well differentiated pNETs requiring systemic therapy, according to current recommendations, a combination of streptozocin and 5-fluorouracil should be used in patients with metastatic well differentiated pNETs. Patient concerns We write about three therapy-nave patients with metastatic G2 pNETs treated with STZ/5-FU, which has maintained disease control for longer than 36 months. COMMENTS OUTCOMES In our 3 patients with metastatic G2 pNETs, STZ/5-FU induced long-term disease control over 44, 42, and 95 months, respectively. Lessons Learn More STZ/5-FU can be administered safely in patients with metastatic G2 pNETs achieving disease control.

Source link: https://europepmc.org/article/MED/35089197


Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial.

Background: Background Cytotoxic chemotherapy mixtures and targeted agents represent well established treatment options for advanced pancreatic neuroendocrine tumors. In progressive advanced PNET patients, the RamuNET trial aims to determine the effectiveness of dual therapy with DTIC and ramucirumab. Methods The RamuNET study is an investigator-initiated multicenter prospective single-arm trial to determine the safety of ramucirumab in combination with dacarbazine over a period of at least six months. The sample size calculation was determined based on an exact binomial single-stage model, based on the assumption that 80% of patients will achieve disease control after 6 months. Discussion This paper looks at a new therapeutic strategy that uses a combination of cytotoxic and targeted antiangiogenic therapy in advanced PNET. This trial will be the basis for a multi-arm research into the use of ramucirumab and DTIC against other commonly used drugs in PNET if positive.

Source link: https://europepmc.org/article/MED/34772353

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions